SCHEMBL9907646

SCHEMBL9907646

Cc1nc2ccc(C(=O)O)cc2c(-c2ccncc2Cl)c1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 14/20 0.46
CSNK2B P67870 14/20 0.46
TDP1 Q9NUW8 2/20 0.46
ALDH1A1 P00352 2/20 0.45
POLB P06746 2/20 0.45
HPGD P15428 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
CSNK2A1 P68400 6/20 0.42
PIM1 P11309 1/20 0.42
PIM2 Q9P1W9 1/20 0.42
HTR5A P47898 1/20 0.41
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
USP2 O75604 1/20 0.40
APOBEC3A P31941 1/20 0.40
HTT P42858 1/20 0.40
YWHAG P61981 1/20 0.40
KMT2A Q03164 1/20 0.40
HSD17B10 Q99714 1/20 0.40
APOBEC3G Q9HC16 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9907634 0.87 ALDH1A1 (0.55) ALDH1A1HPGDL3MBTL1KDM4EHSD17B10
SCHEMBL9907907 0.86 HTR5A (0.60) HTR5A
SCHEMBL9907632 0.84 KMT2A (0.49) TDP1ALDH1A1POLBHPGDL3MBTL1
SCHEMBL9907644 0.81 HTR5A (0.48) TDP1ALDH1A1POLBHPGDL3MBTL1
SCHEMBL16502703 0.79 CSNK2A2 (0.45) CSNK2A2CSNK2BL3MBTL1CSNK2A1PIM1
SCHEMBL16502670 0.76 CSNK2A2 (0.46) CSNK2A2CSNK2BCSNK2A1PIM1PIM2
SCHEMBL9907738 0.75 HTR5A (0.58) CSNK2A2CSNK2BTDP1ALDH1A1POLB
SCHEMBL9907721 0.74 ALDH1A1 (0.50) TDP1ALDH1A1POLBHPGDL3MBTL1
SCHEMBL9907579 0.74 LMNA (0.54) CSNK2A2CSNK2BTDP1ALDH1A1POLB
SCHEMBL9907631 0.74 HTR5A (0.51) TDP1ALDH1A1POLBHPGDL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E CSNK2A2 4132/4885CSNK2B 4303/4885TDP1 964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.